Genoscience Pharma completes successful phase 1b trial evaluating GNS561, PPT-1 inhibitor, in patients with primary and secondary liver cancer
- Company identified recommended phase 2 dose for continued clinical development of GNS561 in patients with hepatocarcinoma and other cancers
- Based on preclinical and clinical phase 1 data, GNS561 is moving forward in phase 2/3 studies in hepatocarcinoma in combination with immune checkpoint inhibitors, in patients where standard of care failed or was stopped for safety reason
- Genoscience Pharma is in ongoing discussion with potential partners regarding patient enrollment in 2021
Marseille, France, November 18, 2020 – Genoscience Pharma, a clinical stage biotechnology company developing unique lysosomotropic drug candidates for the treatment of cancer, auto-immune and infectious diseases through autophagy modulation, announces today the successful completion of a phase 1b clinical study with GNS561, its lead candidate, in primary and secondary liver cancer patients. The company is planning to start phase 2 trials in 2021.
